Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 2
1998 4
1999 2
2000 1
2001 2
2002 2
2003 4
2004 8
2005 8
2006 5
2007 3
2008 3
2009 1
2010 1
2011 1
2012 2
2013 4
2014 6
2015 6
2016 3
2017 3
2018 4
2019 9
2020 4
2021 3
2022 8
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trümper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Savage KJ, et al. Among authors: alpdogan o. Blood Adv. 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971. Blood Adv. 2022. PMID: 35470385 Free PMC article. Clinical Trial.
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Haverkos B, et al. Among authors: alpdogan o. Blood Adv. 2023 Oct 24;7(20):6339-6350. doi: 10.1182/bloodadvances.2023010330. Blood Adv. 2023. PMID: 37530631 Free PMC article. Clinical Trial.
Systemic therapy of cutaneous T-cell lymphoma (CTCL).
Alpdogan O, Kartan S, Johnson W, Sokol K, Porcu P. Alpdogan O, et al. Chin Clin Oncol. 2019 Feb;8(1):10. doi: 10.21037/cco.2019.01.02. Chin Clin Oncol. 2019. PMID: 30818958 Free article. Review.
Immune tolerance and transplantation.
Alpdogan O, van den Brink MR. Alpdogan O, et al. Semin Oncol. 2012 Dec;39(6):629-42. doi: 10.1053/j.seminoncol.2012.10.001. Semin Oncol. 2012. PMID: 23206840 Free PMC article. Review.
Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS).
Oluwasanjo A, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A, Haverkos BM, Gong J, Porcu P. Oluwasanjo A, et al. Among authors: alpdogan o. Cancer Treat Res. 2019;176:83-98. doi: 10.1007/978-3-319-99716-2_4. Cancer Treat Res. 2019. PMID: 30596214 Review.
Implementation of an Outpatient HD-MTX Initiative.
Sokol K, Yuan K, Piddoubny M, Sweeney E, Delengowski A, Fendler K, Espinosa G, Alberto J, Galanis P, Gung C, Stokley M, George M, Harris M, Martinez-Outschoorn U, Alpdogan O, Porcu P, Binder AF. Sokol K, et al. Among authors: alpdogan o. Front Oncol. 2022 Jan 20;11:773397. doi: 10.3389/fonc.2021.773397. eCollection 2021. Front Oncol. 2022. PMID: 35127480 Free PMC article.
The spectrum of CD30+ T cell lymphoproliferative disorders in the skin.
Kartan S, Johnson WT, Sokol K, Alpdogan O, Gru AA, Nikbakht N, Porcu P. Kartan S, et al. Among authors: alpdogan o. Chin Clin Oncol. 2019 Feb;8(1):3. doi: 10.21037/cco.2018.12.03. Epub 2019 Jan 9. Chin Clin Oncol. 2019. PMID: 30691273 Free article. Review.
92 results